Icure Pharmaceutical Incorporation (175250) — Cash Flow Reinvestment Rate

Latest as of June 2020: 83.70x

Icure Pharmaceutical Incorporation (175250) has a Cash Flow Reinvestment Rate of 83.70x as of June 2020, reinvesting ₩16.36 Billion (capex ₩7.44 Billion plus investments ₩8.92 Billion) from operating cash flow of ₩195.44 Million. Check cash flow quality index of Icure Pharmaceutical Incorporation to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

83.70x
(Capex + Investments) / Operating CF

Total Reinvested

₩16.36 Billion
Capex + Investments

Operating Cash Flow

₩195.44 Million
KRW

Capital Expenditures

₩7.44 Billion
KRW

Icure Pharmaceutical Incorporation Cash Flow Reinvestment Rate (2017–2017)

Historical reinvestment intensity for Icure Pharmaceutical Incorporation across 1 annual periods. Explore how much of Icure Pharmaceutical Incorporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Icure Pharmaceutical Incorporation (2017–2017)

Year-by-year capital reinvestment analysis for Icure Pharmaceutical Incorporation. For live market cap and broader valuation context, see Icure Pharmaceutical Incorporation (175250) total market value.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2017 9.20x ₩10.30 Billion ₩1.12 Billion ₩10.10 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow